A recent decision from the Court of Appeals for the First Circuit has upheld an injunction on proposed federal funding cuts to National Institutes of Health (NIH) grants for medical research. The appellate court’s ruling, delivered by a three-judge panel, came as a relief to many in the medical research community. The court found that the district court had appropriately exercised its jurisdiction over the plaintiffs’ claims, noting that the cuts would likely exceed the authority granted to NIH by Congress and existing regulations.
The plaintiffs, comprised of 22 attorneys general, multiple medical associations, and numerous higher education institutions, argued that the proposed adjustments would lead to layoffs, laboratory closures, and the stalling of clinical trials. The appellate court emphasized the vital role that NIH funding plays in advancing medical research, citing its contributions to discovering treatments for diseases such as cancer and diabetes, and its role in reducing death rates from acute conditions and understanding infectious diseases. This sentiment was reflected in the court’s decision, stating that the public health benefits derived from NIH-funded research are substantial.
Historically, medical research funding from the NIH has been distributed on a reimbursement basis, covering both direct and indirect costs. Direct costs are specific to individual projects, while indirect costs span multiple projects, encompassing expenses like facility maintenance. Traditionally, these costs are calculated as a percentage of direct costs, negotiated between the NIH and grant recipients through a “negotiated indirect cost rate agreement” (NICRA). The proposed cuts, however, aimed to cap indirect cost reimbursements at 15 percent of direct expenses, a significant departure from the existing model. This approach prompted the plaintiffs to challenge the cap’s legality, arguing it overstepped NIH’s authority.
NIH contested the district court’s jurisdiction, invoking the Tucker Act, which directs contractual disputes with the federal government to the Court of Federal Claims. It contended that NICRAs represented such contracts. However, the appellate court dismissed this argument, referencing two recent Supreme Court cases to explain that the challenge was against a regulation, not the NICRAs themselves. This distinction allowed the case to proceed in the district court, as plaintiffs were contesting the broader policy, not a specific financial withholding.
The appellate court’s analysis extended to congressional directives, determining that the reimbursement cap likely exceeded NIH’s allowed authority, as Congress had specifically mandated against a universal indirect cost rate. This decision, developed over February’s initial lawsuits and March’s district court rulings, found the proposed cap to be arbitrary and capricious, thus supporting the preliminary injunction.
For a deeper dive into the judicial process and the court’s reasoning, further details can be accessed here.